Etanercept: An overview

J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S105-11. doi: 10.1016/mjd.2003.554.

Abstract

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

Publication types

  • Review

MeSH terms

  • Arthritis, Psoriatic / drug therapy*
  • Arthritis, Psoriatic / immunology
  • Etanercept
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / pharmacology*
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Tumor Necrosis Factor-alpha / drug effects*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept